表紙
市場調査レポート

PharmaPoint:B型肝炎ウイルス(HBV)予防ワクチン - 現在/将来の主要企業

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players

発行 GlobalData 商品コード 299715
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
PharmaPoint:B型肝炎ウイルス(HBV)予防ワクチン - 現在/将来の主要企業 PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players
出版日: 2014年01月31日 ページ情報: 英文 70 Pages
概要

当レポートでは、急速に成長しているB型肝炎ウイルス(HBV)予防ワクチン市場について取り上げ、新規参入を含めた競合情勢に焦点を当てて、主要企業に関する最新情報と詳細な分析を提供し、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進要因・障壁 - 世界の問題点

第4章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • GSK
    • Merck
    • Sanofi
    • Kaketsuken
    • Dynavax Technologies

第5章 付録

図表

目次
Product Code: GDHC1028FPR

GlobalData has released its pharma report, "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for prophylactic hepatitis B virus vaccines
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of prophylactic hepatitis B virus vaccines sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving prophylactic hepatitis B virus vaccines market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global prophylactic hepatitis B virus vaccines market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. GSK
    • 4.3.2. Merck
    • 4.3.3. Sanofi
    • 4.3.4. Kaketsuken
    • 4.3.5. Dynavax Technologies

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Patient Populations Targeted for Vaccination
    • 5.4.2. Vaccination Coverage Rates
    • 5.4.3. Vaccinated Patients
    • 5.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 5.4.5. General Pricing Assumptions
  • 5.5. Physicians and Specialists Included in this Study
    • 5.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 5.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 5.6. About the Authors
    • 5.6.1. Analyst
    • 5.6.2. Therapy Area Director
    • 5.6.3. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for HBV Vaccines, 2012-2022
  • Table 2: Global HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 3: Key Companies in the HBV Vaccine Market, 2014
  • Table 4: GSK's HBV Vaccine Portfolio Assessment, 2014
  • Table 5: GSK SWOT Analysis, 2014
  • Table 6: Merck's HBV Vaccine Portfolio Assessment, 2014
  • Table 7: Merck SWOT Analysis, 2014
  • Table 8: Sanofi's HBV Vaccine Portfolio Assessment, 2014
  • Table 9: Sanofi SWOT Analysis, 2014
  • Table 10: Kaketsuken's HBV Vaccine Portfolio Assessment, 2014
  • Table 11: Kaketsuken SWOT Analysis, 2014
  • Table 12: Dynavax Technologies' HBV Vaccine Portfolio Assessment, 2014
  • Table 13: Dynavax Technologies SWOT Analysis, 2014
  • Table 14: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
  • Table 15: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales for HBV Vaccines by Country, 2012-2022
  • Figure 2: Global Sales for HBV Vaccines by Company, 2012-2022
  • Figure 3: Company Portfolio Gap Analysis in HBV Vaccines, 2012-2022
Back to Top